MeSH note : consists of CD54-positive PA2024-loaded antigen presenting cells with admixtures of
monocytes, macrophages, and B and T cells; proposed prostate cancer vaccine;
https://www.ema.europa.eu/medicines/human/EPAR/Provenge 2013 United Kingdom French English sipuleucel-T sipuleucel-T sipuleucel-T drug approval europe treatment outcome adult prostatic neoplasms neoplasm metastasis summary of product characteristics package leaflet drug evaluation syndication feed immunotherapy survival analysis infusions, intravenous leukapheresis product surveillance, postmarketing prostatic acid phosphatase prostatic neoplasms antigen-presenting cells protein tyrosine phosphatases tissue extracts tissue extracts
--- https://www.cadth.ca/sites/default/files/pdf/E0037_Sipuleucel-T_prostate_cancer_cetap_f.pdf https://www.cadth.ca/sites/default/files/pdf/E0037_Sipuleucel-T_prostate_cancer_cetap_e.pdf 2007 Canada English French tissue extracts prostatic neoplasms prostatic neoplasms immunotherapy, active treatment outcome canada tissue extracts tissue extracts cancer vaccines cancer vaccines cancer vaccines clinical trials as topic Evidence-Based medicine survival analysis infusions, intravenous sipuleucel-T sipuleucel-T sipuleucel-T sipuleucel-T drug evaluation